We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL).
- Authors
Michot, J. M.; Chavez, J.; Carpio, C.; Bachy, E.; Ferrari, S.; Morschhauser, F.; Jørgensen, J. M.; Cordoba, R.; Bories, P.; Patah, P.; de Moucheron, B.; Carrancio, S.; Guarinos, C.; Zheng, X.; Mei, C.; Pourdehnad, M.; Nastoupil, L.
- Abstract
Here, we report updated efficacy results for CC-99282 monotherapy (part A) and new safety data for CC-99282 + RTX (part B). B Introduction: b CC-99282 is a novel, oral, small molecule CELMoD® agent that co-opts cereblon to induce targeted degradation of Ikaros/Aiolos, transcription factors critical for B-cell malignancy development. OPEN-LABEL PHASE 1/2 STUDY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL).
- Subjects
UBIQUITIN ligases; NON-Hodgkin's lymphoma; RITUXIMAB; DIFFUSE large B-cell lymphomas
- Publication
Hematological Oncology, 2023, Vol 41, p134
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_90